Thursday, 23 Jan 2020

You are here

Tofacitinib Efficacy Revealed in OPAL Study

Pfizer has issued a press release of its preliminary results from the OPAL study that examined the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily (BID) in adults active psoriatic arthritis (PsA).

422 PsA patients, on background DMARD therapy, were randomized to receive tofacitinib (5 mg or 10 mg BID), adalimumab 40 mg q2 wk (active control) or  placebo in a phase III trial.

The primary efficacy endpoint was met with ACR20 responses for both tofacitinib 5 mg BID and 10 mg BID being superior to placebo at 3 months. Disappointingly, no numeric results were released for comparison and magnitude of benefit.

These presumeably positive results in PsA contrast the less-than-expected results in psoriasis only patients, where recent clinical trials demonstrated that tofacitinib 5 mg bid was inferior to etanercept, but 10 mg bid was equal to etanercept in PASI 75 responses.
 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.

Best of 2019 - ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).

Upadacitinib Effective in Ankylosing Spondylitis

Lancet reports that the selective JAK1 inhibitor, upadacitinib, was effective when given to patients with active ankylosing spondylitis.

Secukinumab Improves Enthesitis

Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week.